NEW YORK (GenomeWeb News) – Microbioal genetic analysis firm OpGen today announced it has received Clinical Laboratory Improvement Amendments certification.
As a result, the Gaithersburg, Md.-based firm is launching its clinical services lab focused on developing genetic tests and analysis services for surveilling and identifying healthcare-associated infections and human pathogens.
OpGen's clinical services lab uses next-generation DNA and genetic analysis technology, including multiplex real-time PCR, whole genome mapping, and next-generation sequencing. As a result, it can offer low cost genetic testing for the screening, surveillance, diagnosis, gene content, and epidemiological analysis of infectious diseases, it said.
It offers whole genome mapping genetic analysis of HAIs, and sequence analysis of C. difficile on a worldwide basis, and it will offer real-time PCR screening and surveillance of MRSA and complete C. difficile hypervirulence diagnostic testing services in the mid-Atlantic region.
Additionally, OpGen is developing tests for gram-negative and gram-positive multidrug resistant organisms, it said.
"OpGen is building on the success of our whole genome mapping applications in the public health and life sciences sectors to expand our capabilities to help hospitals and healthcare facilities combat HAIs and complex human pathogens, OpGen CEO Douglas White said in a statement. "With the opening of our CLIA-certified laboratory, OpGen will provide a unique, comprehensive offering of infectious disease screening, diagnostic, and epidemiology services."